BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

Andrea Visentin, Silvia Imbergamo, Edoardo Scomazzon, Stefano Pravato, Federica Frezzato, Laura Bonaldi, Marco Pizzi, Stefania Vio, Michele Gregianin, Marta Burei, Monica Facco, Gianpietro Semenzato, Francesco Piazza, Livio Trentin

Research output: Contribution to journalArticle

Original languageEnglish
Number of pages4
JournalBritish Journal of Haematology
DOIs
Publication statusE-pub ahead of print - Jul 5 2018

Keywords

  • Chronic lymphocytic leukaemia
  • Ibrutinib
  • Idelalisib
  • Lenalidomide
  • Richter syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Visentin, A., Imbergamo, S., Scomazzon, E., Pravato, S., Frezzato, F., Bonaldi, L., Pizzi, M., Vio, S., Gregianin, M., Burei, M., Facco, M., Semenzato, G., Piazza, F., & Trentin, L. (2018). BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. British Journal of Haematology. https://doi.org/10.1111/bjh.15440